Experienced in Scleroderma

Kilian Eyerich

Hugstetter Str. 55, 
Freiburg, BW, DE 
Experienced in Scleroderma
Hugstetter Str. 55, 
Freiburg, BW, DE 
OverviewLocationsClinical Research

Overview

Kilian Eyerich practices in Freiburg, Germany. Mr. Eyerich is rated as an Experienced expert by MediFind in the treatment of Scleroderma. His top areas of expertise are Atopic Dermatitis, Psoriasis, Plaque Psoriasis, and Darier Disease.

His clinical research consists of co-authoring 214 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 4 articles in the study of Scleroderma.

Gender
Male

Locations

Hugstetter Str. 55, Freiburg, BW 79106, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Safety and Efficacy of Baricitinib in Combination With Topical Corticosteroids in Adult Patients With Moderate-to-Severe Atopic Dermatitis Who Have Experienced Failure to Cyclosporine or Are Intolerant to, or Have Contraindication to, Cyclosporine
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drugs: Baricitinib, Corticosteroid
Study Phase: Phase 3
An Investigator-initiated, Randomized, Double-blind, Placebo Controlled Study of Apremilast to Demonstrate Efficacy in Subjects With Nummular Eczema
An Investigator-initiated, Randomized, Double-blind, Placebo Controlled Study of Apremilast to Demonstrate Efficacy in Subjects With Nummular Eczema
Enrollment Status: Completed
Publish Date: October 08, 2021
Intervention Type: Drug
Study Drug: Apremilast
Study Phase: Phase 2
View 1 Less Clinical Trial

214 Total Publications

Lebrikizumab improves head/neck/face dermatitis and erythema and does not increase treatment-emergent adverse events of head/neck/face erythema in patients with moderate-to-severe atopic dermatitis.
Lebrikizumab improves head/neck/face dermatitis and erythema and does not increase treatment-emergent adverse events of head/neck/face erythema in patients with moderate-to-severe atopic dermatitis.
Journal: The Journal of dermatological treatment
Published: July 25, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Eyerich's expertise for a condition
ConditionClose
View All 37 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile